GlassScriptPhysician profile
Ashley A Johnson
NPI 1790267227
$7,227.39
in general payments reported to CMS, 2019-2025
33 companies · $1,856 in 2025
The $1,856 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $769 · 2022: $1,100 · 2023: $1,203 · 2024: $2,300 · 2025: $1,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,400 · Honoraria: $850 · Education: $99.23 · Consulting Fee: $9.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,400.05 |
| Honoraria | $850.00 |
| Education | $99.23 |
| Consulting Fee | $9.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,280.92 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,474.75 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Blueprint Medicines Corporation | $790.80 | 2023-2025 | Ayvakit |
| Aimmune Therapeutics, INC. | $375.00 | 2022-2024 | |
| Amgen INC. | $279.18 | 2021-2025 | Tezspire, Actimmune |
| Glaxosmithkline, LLC. | $244.72 | 2021-2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $201.61 | 2021-2025 | Takhzyro, Hyqvia, Cuvitru |
| Regeneron Healthcare Solutions, INC. | $171.03 | 2021-2025 | Dupixent |
| Pfizer INC. | $169.75 | 2021-2025 | |
| Csl Behring | $155.83 | 2022-2025 | Hizentra, Haegarda |
| Novartis Pharmaceuticals Corporation | $122.65 | 2022-2025 | |
| Mentor Worldwide LLC | $112.24 | 2021-2024 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander, Mentor Memoryshape Breast Implant |
| Abbvie INC. | $94.51 | 2022-2023 | |
| Octapharma USA, INC. | $91.52 | 2024-2025 | Octagam Immune Globulin (Human) |
| Optinose US, INC. | $82.76 | 2021-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $73.01 | 2021-2023 | Auvi-Q |
| Grifols USA, LLC | $60.29 | 2022-2023 | Prolastin-C Liquid |
| Genentech USA, INC. | $53.54 | 2021-2025 | Xolair |
| Pharming Healthcare, INC. | $51.02 | 2021-2025 | Ruconest |
| Genentech, INC. | $49.35 | 2021 | |
| Sanofi-Aventis U.S. LLC | $35.91 | 2021 | |
| Hospira, INC. | $33.88 | 2024-2025 | |
| Alk-Abello, INC | $29.90 | 2022 | |
| Biocryst US Sales Co., LLC | $28.27 | 2024 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.62 | 2022-2023 | Spiriva Respimat, Stiolto Respimat |
| Incyte Corporation | $23.53 | 2023 | Opzelura |
| Corium, LLC | $20.47 | 2022 | |
| Horizon Therapeutics Plc | $19.29 | 2021 | |
| Abiomed | $18.88 | 2024 | Impella |
| Lilly USA, LLC | $16.29 | 2025 | Ebglyss |
| Arcutis Biotherapeutics, INC. | $16.21 | 2025 | Zoryve |
| Mylan Specialty L.P. | $14.59 | 2021 | |
| Adma Biomanufacturing LLC | $9.07 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.